Literature DB >> 19052470

Efficacy of a negative conversion trial and subsequent living donor kidney transplant outcome in recipients with a positive lymphocyte crossmatch.

Kyu Ha Huh1, Soon Il Kim, Dong Jin Joo, Man Ki Ju, Hye Kyung Chang, Hae Jin Kim, Yu Seun Kim, Myoung Soo Kim.   

Abstract

BACKGROUND: Patients with a positive lymphocyte crossmatch (LCX) do not undergo kidney transplantation. In such patients, a negative conversion protocol consisting of intravenous immunoglobulin (IVIG), plasmapheresis, and potent immunosuppressant is one of the options for transplantation.
METHODS: 14 patients who showed a positive LCX with living donors underwent a trial of negative conversion between January 2002 and July 2007. Plasmapheresis was performed every other day, up to 6 times maximum. IVIG was infused after plasmapheresis, with a total dose of 500 mg/kg divided over 6 days. Kidney transplantation was performed immediately after negative conversion. Anti-thymocyte globulin (ATG) or OKT3 induction therapy was used with the combination of tacrolimus, mycophenolate mofetil, and prednisone in the perioperative period.
RESULTS: Negative conversion of LCX was achieved in 13 of 14 patients (92.9%). Transplantations were performed successfully in these 13 patients without hyperacute rejection. Four recipients developed acute rejection, which was well controlled by steroid pulse therapy. During the follow-up periods of 45.4 +/- 22.0 months, all recipients except 1 showed excellent graft function.
CONCLUSION: Selected patients with a positive LCX can undergo successful transplantation using plasmapheresis, IVIG, and potent immunosuppressants. Recipients with negative conversion of LCX showed acceptable posttransplant results. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19052470     DOI: 10.1159/000178979

Source DB:  PubMed          Journal:  Nephron Clin Pract        ISSN: 1660-2110


  1 in total

1.  Kidney transplantation after desensitization in sensitized patients: a Korean National Audit.

Authors:  Kyu Ha Huh; Beom Seok Kim; Jaeseok Yang; Jeongmyung Ahn; Myung-Gyu Kim; Jae Berm Park; Jong Man Kim; Byung-Ha Chung; Joong Kyung Kim; Jin Min Kong
Journal:  Int Urol Nephrol       Date:  2012-04-15       Impact factor: 2.370

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.